2 -Adrenergic Receptor Pharmacogenetics
|
|
- Randell Francis
- 6 years ago
- Views:
Transcription
1 2 -Adrenergic Receptor Pharmacogenetics STEPHEN B. LIGGETT Departments of Medicine (Pulmonary) and Molecular Genetics, University of Cincinnati College of Medicine, Cincinnati, Ohio 2 -Adrenergic receptors ( 2 ARs) expressed on airway smooth muscle are the targets for -agonists used in the treatment of bronchospasm. Studies have shown that this receptor is polymorphic within the human population and that some of these polymorphic receptors have different pharmacologic properties. In this review three areas are addressed regarding these polymorphisms: established concepts, clinical studies that need confirmation, and future directions. ESTABLISHED CONCEPTS Genetics The human 2 AR is encoded by an intronless gene, with a coding block consisting of 1,239 nucleic acids. Within this region there are nine known loci that vary within the normal population (1). The nucleic acid changes within the context of the codons are shown in Figure 1, which depicts the amino acid sequence and proposed membrane topography of the 2 AR. As might be predicted, the single nucleotide polymorphisms (SNPs) are randomly located throughout the sequence. As shown, five of these do not result in a change in the encoded amino acid. However, four polymorphisms result in variation in the encoded residues at amino acids 16, 27, 34, and 164. We initially discovered these by direct dideoxy sequencing of polymerase chain reaction (PCR) products derived from overlapping primers designed to span the open reading frame. Subsequent studies have failed to reveal any additional nonsynonymous polymorphisms, nor have we found any variants consisting of deletions of truncations of the receptor. The original description of the human gene has been used to define the wild-type sequence, although it is clear that in some cases this is not the most frequent allele (Table 1). The most common polymorphisms are in the amino terminus of the receptor at amino acid position 16, where Arg or Gly can be found, and position 27, where Gln or Glu is common. A rare variant has been found at position 34, with an allele frequency of 1%. At position 164, Thr (wild type) or Ile can be found, although the latter is somewhat uncommon (heterozygous state has been found in 3 5% of the population). Although not extensively studied, we have found that the frequencies of the position 16 and 27 variants differ between white, black, and Asian populations. In one report, we found that the allele frequencies for Gly-16 were 0.61, 0.50, and 0.40 for the three respective ethnic groups, and for Gln-27 they were 0.57, 0.73, and In our initial case-control study, we found no difference in the frequencies of these polymorphisms between a heterogeneous asthmatic group and a nonasthmatic cohort (1). This lack of association with asthma has been reported by others as well (2 4). One study, carried out in children, did report a significant association with childhood asthma and the Gln-27 Correspondence and requests for reprints should be addressed to Stephen B. Liggett, M.D., University of Cincinnati College of Medicine, 231 Bethesda Avenue, Room 7511, P.O. Box , Cincinnati, OH stephen. liggett@uc.ed; Internet: Am J Respir Crit Care Med Vol 161. pp S197 S201, 2000 Internet address: genotype. However, given that the 2 AR gene is localized to chromosome 5q 31 32, and microsatellite markers in this region have been linked to asthma, bronchial hyperresponsiveness, or atopy in family studies, it is generally accepted that this finding with the 2 AR polymorphism is due to its being in linkage disequilibrium with a nearby disease-causing gene. We have begun to investigate the 5 untranslated region of the 2 AR for polymorphism (5). In this region a 19-amino acid peptide is encoded by a 5 leader cistron sequence (6). This peptide has been shown to modify 2 AR translation and thus the level of cellular expression. Critical elements of the peptide include arginines in its carboxy-terminal region (6). As shown in Figure 1, a single nucleotide polymorphism has been identified in the last codon of the cistrons, such that Arg or Cys can be present with allele frequencies of 0.37 and 0.63, respectively. Neither allele is more common in subjects with asthma (S. B. Liggett, unpublished observation, 1999). As is subsequently discussed, the preceding polymorphism of the 5 leader cistron and those of the coding block clearly alter receptor expression, function, or regulation. With the three most common loci, we have been able to assess the relative frequencies of the various genotypic combinations (Table 2). As can be seen, several combinations are present at reasonable frequencies, some are uncommon, and others were not found. From Table 2 several other observations can be made. First, it appears that within the coding block, the Arg- 16/Glu-27 genotypic combination is rare. This is due to linkage disequilibrium at these two close loci (4). So, when Arg-16 is present the likelihood of Gln being at position 27 is high. When Gly-16 is present, Glu-27 is more likely than Gln-27, but both combinations are observed. These results were obtained by methods that do not distinguish from which parental chromosome the polymorphisms arise. Thus haplotypes can only be inferred. To determine true haplotypes, specific techniques need to be employed. It would then be known exactly which two receptors, taking into account all polymorphic loci, are encoded. Such haplotyping has not been extensively performed to date, but as discussed below may be an important consideration. Finally, one report has identified additional polymorphisms in the 5 upstream region (7). These occur at nucleotides 20, 367, 468, 654, 1023, 1343, and Functional Consequences Before embarking on additional clinical studies, our approach was to determine if these polymorphisms altered receptor function (5, 8 10). If so, then hypothesis-based clinical studies could be rationally designed. The results from such clinical studies are likely to be much more convincing if they are backed by results from cell- or transgenic mouse-based mechanistic studies. This scenario is in contrast to what might occur in association studies with a polymorphism of unknown relevance to protein function. The methods we have used for determining the functional relevance of these polymorphisms have been delineated in detail (8, 9) and reviewed elsewhere (11 13). The approach has been to mimic the polymorphisms by site-directed mutagenesis, then to express the variant receptor in host cells that lack
2 S198 AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE VOL Figure 1. Amino acid sequence of the human 2 AR and its 5 leader cistron. Shown are the location of polymorphisms in the DNA sequence that result in variation in amino acids at the indicated positions. The darkened circles indicate codons where the DNA sequence is variable but does not result in variation in the encoded amino acid. Nucleic Acid Position TABLE 1 POLYMORPHISMS OF THE 2 -ADRENERGIC RECEPTOR Nucleic Acid Amino Acid Position Wild Type Polymorphism (Allele Frequency) 46 A or G 16 Arg Gly (0.61) 79 C or G 27 Gln Glu (0.43) 100 G or A 34 Val Met ( 0.001) 491 C or T 164 Thr ILe (0.05)* 47 C or T 19LC Arg Cys (0.63) Definition of abbreviation: LC leader cistron. *Heterozygote frequency; no homozygous Ile-164 individuals found to date. AR expression. Pharmacologic and biologic properties are then assessed. Typically, the effects of these polymorphisms on receptor expression, agonist- and antagonist-binding affinities, physical and functional coupling to stimulatory G protein (G s ), receptor trafficking, and receptor regulation by agonist are assessed. The results of these types of studies carried out in Chinese hamster fibroblasts expressing the different human polymorphic receptors of the 2 AR are summarized in Table 3. The Ile-164 receptor has an approximately threefold decreased affinity for isoproterenol, epinephrine, and norepinephrine (8). More dramatic is the decrease in basal and agonist-stimulated adenylyl cyclase activities (Figure 2). The latter series of studies suggested that the conformation of the receptor is altered such that spontaneous toggling to the activated state, and agonist-stabilized activation, is significantly decreased in the Ile-164 receptor. Consistent with this notion, agonist competition studies in the absence of guanine nucleotide showed that the Ile-164 receptor failed to display highaffinity agonist receptor G s interactions (8). The Ile-164 receptor has been expressed in the hearts of transgenic mice and a similar coupling defect has also been observed in receptor signaling (14). In addition, physiologic studies of these mice examining inotropic and chronotropic responses revealed that the Ile-164 receptor is substantially impaired in vivo. We have shown that this polymorphism has a significant disease-modifying effect in congestive heart failure (15), where 2 AR function may be particularly important since 1 AR are downregulated. Individuals with an Ile-164 polymorphism had an increased risk of death or transplant compared with those with Thr-164 with a relative risk of 4.81 (p 0.001). In contrast to the above, polymorphisms at positions 16 and 27 do not alter agonist affinity or coupling to G s (9). However, agonist-promoted trafficking is altered. As shown in Figure 3A, long-term, agonist-promoted downregulation of receptor number is enhanced when Gly is present at position 16, and is absent when Glu is at position 27 (with Arg at position 16). This difference in downregulation is due to alterations in receptor degradation after the internalization step (9). Interestingly, when both polymorphisms are present (Gly-16/Glu-27), the downregulation is similar to that of Gly-16 receptors, suggesting that this locus may dominate the phenotype when Gly is present. These studies have also been carried out in human airway smooth muscle cells, where endogenous expression of receptors (i.e., not a transfection-based study) was examined in primary culture of cells from various individuals with different 2 AR genotypes. As shown in Figure 3B, downregulation was greater in Gly-16 cells compared with Arg-16 cells, and was minimal in cells expressing the Glu-27 receptor. TABLE 2 GENOTYPIC COMBINATIONS OF THE COMMON 2 AR POLYMORPHISMS Genotype* 5 LC19 cb16 cb27 No. Percentage of Total Het Het Het Het Gly Het Cys Arg Gln Arg Gly Glu Cys Het Gln Cys Gly Gln Het Het Gln Arg Gly Het Cys Het Het Het Gly Gln *5 LC 2 AR 5 leader cistron; cb 2 AR coding block; Het heterozygous; Arg, Cys, Gln, and Glu represent homozygous alleles at these positions.
3 Liggett: 2 -Adrenergic Receptor Pharmacogenetics TABLE 3 CELLULAR PHENOTYPES OF 2 AR POLYMORPHISMS Nucleic Acid Amino Acid No. Designation Phenotype Arg-16 Reference Gly-16 Enhanced downregulation Gln-27 Reference Glu-27 Absent downregulation Val-34 Reference Met-34 Normal Thr-164 Reference Ile-164 Decreased coupling, binding and sequestration LC Arg Reference LC Cys Increased expression The polymorphism in the 5 leader cistron was found to alter receptor expression. This was examined by constructing vectors having identical sequence in the 5 untranslated region and the coding block except at nucleotide 47. COS-7 cells were transfected with these constructs and expression was quantitated by radioligand binding. As shown, there was a consistently greater 2 AR expression that occurred with the 5 LC Cys-19 construct as compared with the 5 LC Arg-19 construct. Similar experiments, carried out by cotransfection of a firefly luciferase gene to control for transfection efficiency, again showed greater expression of the 5 LC Cys-19 construct. Importantly, 2 AR mrna levels were the same in these cells, pointing toward differences in protein translation rather than mrna transcription, consistent with the role of the leader cistron peptide. Scott and coworkers have reported evidence that four of the polymorphisms in the 5 upstream region are within the first 500 bp of the 5 untranslated region, which may be of functional significance in regard to receptor expression (7). It is not clear, however, whether most of this control is due to the aforementioned polymorphism (5) at nucleotide 47, or whether there are contributions from the polymorphisms at nucleotides 20, 367, and 468. CLINICAL STUDIES OF AGONIST RESPONSIVENESS NEEDING CONFIRMATION As indicated above, the phenotype of the common polymorphisms in the coding block, as assessed in cells, is one of differences in downregulation. Clinically, agonist-promoted downregulation may result in tachyphylaxis, which is defined as a S199 waning of effectiveness of an agonist over time during repetitive administration. If polymorphisms are differentially downregulated in vivo by endogenous catecholamines (as they are in tissue culture), then the initial response to therapy could also be affected. Several studies examining the effect of 2 AR polymorphisms on agonist responsiveness have been reported. Martinez and coworkers (2) examined the bronchodilating response to the administration of a single dose of albuterol in children (mean age, 10 yr). The study group consisted of 191 unaffected children and 78 children with a history of wheezing. Of this latter group 37 had a diagnosis of asthma. In the asthmatic group, 60% of those with homozygous Arg-16 had a positive ( 15.3% increase in FEV 1 ) response to albuterol, compared with 13.3% who were homozygous for Gly-16. While borderline significant (p 0.05 for trend), it should be noted that the homozygous Arg-16 group consisted of only five patients. In addition, the actual changes in FEV 1 were not reported, and so the magnitude of the effect is not clear. Children with a history of wheezing failed to have a significant difference, while unaffected children again showed a greater percentage of positive responses in the homozygous Arg-16 group (p 0.04). When the groups were analyzed together, the odds ratio (adjusted for asthma and wheezing) for having a positive bronchodilator response to albuterol was 5.3 for homozygous Arg-16 children (p 0.007). No associations were noted for the polymorphism at position 27. This study suggests that the initial response to albuterol in children is affected by 2 AR genotype at position 16, although the data concerning children with asthma suffer from a small sample size. The results suggest that the Gly-16 receptor may be chronically downregulated (presumably by endogenous catecholamines), thereby resulting in a depressed response to exogenous agonist. Tan and coworkers (16) examined relationships between tachyphylaxis to 4 wk of treatment with formoterol and 2 AR polymorphisms at positions 16 and 27. Those who were homozygous for Arg-16 displayed essentially no bronchodilator desensitization, while those who were homozygous for Gly-16 were found to have a 46% loss of responsiveness. A similar degree of tachyphylaxis was noted in heterozygotes. No association was found with the position 27 polymorphisms. Of note, the homozygous Arg-16 group consisted of only four patients, and within the Gly-16 group there was a significant amount of variation in bronchodilator desensitization (from a low of 0% to a high of 160%). Besides the small number of patients and the degree of variability within the groups, another concern raised by this study is its lack of agreement with other studies of tachyphylaxis. In most studies, and in general clini- Figure 2. Functional consequences of the Thr-to-Ile polymorphism of the human 2 AR.
4 S200 AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE VOL in the earlier study were associated with 2 AR polymorphisms. Two of 10 markers of asthma control were significantly associated with genotype: subjects homozygous for Gly-16 had no decrease in bronchial responsiveness to methacholine with regular treatment, and those homozygous for Glu-27 had no increase in evening PEF during regular treatment. The study is somewhat complicated by the fact that during regular treatment the majority of patients experienced loss of control, so a comparable number of patients who did not experience this outcome was not available. Nevertheless, the results suggest that 2 AR genotyping has value in predicting these two outcomes during chronic -agonist treatment. It is not altogether clear, however, from the recombinant cell studies how these polymorphisms affect these two parameters under the conditions of the protocol. Additional in vitro studies with fenoterol may reveal agonist-specific phenotypes. Additional clinical studies, which include the 5 leader cistron polymorphism and any other upstream variants, are necessary to further assess these findings. Other studies have investigated the potential for 2 AR polymorphisms to act as disease modifiers. Associations have been found with nocturnal asthma (19), bronchial hyperresponsiveness (20), increased IgE levels (21), and asthma severity (3). These results bring to mind the complexity of considering how polymorphisms of drug targets affect clinical efficacy. Since such polymorphisms may also affect the disease itself, it may be acting in two ways to ultimately alter drug response its disease-modifying effect and its pharmacogenetic effect. FUTURE DIRECTIONS Figure 3. Downregulation (DR) phenotypes of the amino-terminal polymorphisms. Transfected CHW cells (A) or airway smooth muscle cells (B) expressing the indicated polymorphic receptors were exposed to vehicle or isoproterenol (1 M) in cell culture for 24 h and receptor density was determined by radioligand binding. cal experience, only a subset of patients displays tachyphylaxis to -agonists, and this group does not represent the majority of patients. On the basis of the above study, those with the most common allele (Gly-16) undergo significant tachyphylaxis, representing 80% of subjects. Ohe and coworkers (17) used a restriction fragment polymorphism assay, which identifies silent polymorphisms at codon 175, to study subjects from four families. The response to albuterol was examined in 46 individuals. Those who were heterozygous or homozygous for the 2.3-kb allele had an approximately twofold greater responsiveness to this agonist compared with those homozygous for the 2.1-kb allele. It would be interesting to know the genotypes at amino acids 16 and 27, and at position 19 of the 5 leader cistron, in this cohort to compare these results with those of others. Sears and colleagues (18) have reported the genotypes of patients they originally studies in 1990, where they studied the effects of regular versus as-needed fenoterol in a group of 64 subjects with asthma. The earlier report showed a deterioration in asthma control with regular fenoterol as compared with as-needed fenoterol. Clinically, more exacerbations, decreases in FEV 1 and morning peak expiratory flow (PEF), and increased responsiveness to methacholine were noted during regular agonist treatment. These investigators have now determined the 2 AR genotype at positions 16 and 27 in 61 of these subjects to determine whether changes in these variables Interactions between 2 AR Polymorphisms Although the 5 leader cistron and coding block polymorphisms can occur in various combinations, little is known about how they interact since most studies have studied isolated polymorphisms within an otherwise common wildtype sequence. Other 5 untranslated polymorphisms, more recently described, further complicate the picture. Cell-based studies of the common combinations need to be carried out. This will be extremely helpful in providing a sound mechanistic basis for the results of clinical studies in which 2 AR polymorphisms at multiple loci are determined. Within this context determination of the true haplotype will provide the greatest amount of genetic information. Knowing the genotype or haplotype at a few of these loci may provide as much power to predict responsiveness as knowing all of the polymorphisms, given that there is relatively small genetic distance between them. This concept needs to be explicitly tested, however. The fact that several of the preceding clinical studies found associations with position 16 or position 27 polymorphisms but not both suggests that several genotypes will indeed need to be ascertained. Differential Agonist Effects A number of -agonists in common use today differ significantly in structure and/or pharmacologic properties. In vitro studies, as well as clinical trials, need to be carried out with representative agents from each class. It is interesting to consider that the effects of these polymorphisms may be agonist specific, and that knowing the 2 AR genotype may help in selecting a drug with the most favorable predicted response. Alternatively, all -agonists may have the same phenotype, and the presence of certain polymorphisms may indicate the need to use alternative therapeutic agents acting at different targets.
5 Liggett: 2 -Adrenergic Receptor Pharmacogenetics S201 Clinical Response to Agonists As indicated above, control studies with larger patient populations, different levels of asthma severity, and different -agonists need to be carried out to confirm the existing studies. Trials examining the initial response as well as potential tachyphylaxis are necessary. A consensus on a method for defining a loss of clinical efficacy would be helpful since tachyphylaxis is currently studied by a variety of different protocols. Tachyphylaxis to the bronchodilator and bronchoprotective effects of -agonists needs to be considered. Pharmacoethnogenetics As indicated above, there appear to be significant differences in the frequencies of the polymorphisms between ethnic cohorts. It is intriguing to consider whether polymorphisms of the 2 AR may be the basis of differences in asthma phenotype or response to therapy between racial groups. This needs to be explicitly tested in clinical trials. Molecular Basis of the Phenotypes The 2 AR is one of the most extensively studied receptor drug targets in regard to the effects of polymorphic variation on receptor phenotype. Nevertheless, there are a number of questions that remain as to the precise manner by which these specific variances alter receptor function. Knowing more about how these polymorphisms alter function may lead to the development of new -agonists whose functions are not affected by polymorphic variation. CONCLUSIONS The 2 AR is polymorphic within the human population. Cell and transgenic mouse studies have shown that some of these polymorphisms significantly alter function expression, or regulation of the receptor. Most, but not all, clinical studies to date have shown that 2 AR polymorphisms act as disease modifiers or are a determinant of responsiveness to -agonist therapy. Additional studies will be helpful in establishing the predictive role of these polymorphisms in asthma management. Finally, other polymorphisms of asthma drug targets have and continue to be found. Thus, the practice of physicians obtaining an asthma polymorphism panel on patients to further characterize the disease and optimize therapy is quite feasible. IMPORTANT QUESTIONS Are 2 -adrenergic receptor polymorphisms the basis of differences in asthma phenotype or response to therapy among racial groups? Will knowledge of the 2 -adrenergic receptor genotype assist in selecting the drug with the most favorable outcome? Or will all 2 -adrenergic agonists have the same phenotype and the presence of certain polymorphisms indicates the need for alternative therapies directed toward different targets? Will precise knowledge of 2 -adrenergic receptor phenotype variation lead to new 2 -adrenergic agonists whose actions are unaffected by polymorphic variation? Is there a potential for, and a value of, genetically tailored therapy? References 1. Reihsaus, E., M. Innis, N. MacIntyre, and S. B. Liggett Mutations in the gene encoding for the 2 -adrenergic receptor in normal and asthmatic subjects. Am. J. Respir. Cell Mol. Biol. 8: Martinez, F. D., P. E. Graves, M. Baldini, S. Solomon, and R. Erickson Association between genetic polymorphisms of the beta2-adrenoceptor and response to albuterol in children with and without a history of wheezing. J. Clin. Invest. 100: Weir, T. D., N. Mallek, A. J. Sandford, T. R. Bai, N. Awadh, J. M. FitzGerald, D. Cockcroft, A. James, S. B. Liggett, and P. D. Pare Adrenergic receptor haplotypes in mild, moderate and fatal/ near fatal asthma. Am. J. Respir. Crit. Care Med. 158: Dewar, J. C., A. P. Wheatley, A. Venn, J. F. J. Morrison, J. Britton, and I. P. Hall Adrenoceptor polymorphisms are in linkage disequilibrium, but are not associated with asthma in an adult population. Clin. Exp. Allergy 28: McGraw, D. W., E. T. Donnelly, M. G. Eason, S. A. Green, and S. B. Liggett Role of ARK in long-term agonist-promoted desensitization of the 2 -adrenergic receptor. Cell Signal. 10: Parola, A. L., and B. K. Kobilka The peptide product of a 5 leader cistron in the beta 2 adrenergic receptor mrna inhibits receptor synthesis. J. Biol. Chem. 269: Scott, M. G. H., C. Swan, A. P. Wheatley, and I. P. Hall Identification of novel polymorphisms within the promoter region of the human 2 adrenergic receptor gene. Br. J. Pharmacol. 126: Green, S. A., G. Cole, M. Jacinto, M. Innis, and S. B. Liggett A polymorphism of the human 2 -adrenergic receptor within the fourth transmembrane domain alters ligand binding and functional properties of the receptor. J. Biol. Chem. 268: Green, S., J. Turki, M. Innis, and S. B. Liggett Amino-terminal polymorphisms of the human 2 -adrenergic receptor impart distinct agonist-promoted regulatory properties. Biochemistry 33: Green, S. A., J. Turki, P. Bejarano, I. P. Hall, and S. B. Liggett Influence of 2 -adrenergic receptor genotypes on signal transduction in human airway smooth muscle cells. Am. J. Respir. Cell Mol. Biol. 13: Liggett, S. B Functional properties of human 2 -adrenergic receptor polymorphisms. News Physiol. Sci. 10: Liggett, S. B The genetics of 2 -adrenergic receptor polymorphisms: relevance to receptor function and asthmatic phenotypes. In S. B. Liggett and D. A. Meyers, editors. The Genetics of Asthma. Marcel Dekker, New York Liggett, S. B Molecular and genetic basis of 2 -adrenergic receptor function and regulation. In P. Barnes, M. Grunstein, A. Leff, and A. Woolcock, editors. Asthma. Lippincott-Raven, New York Turki, J., J. N. Lorenz, S. A. Green, E. T. Donnelly, M. Jacinto, and S. B. Liggett Myocardial signalling defects and impaired cardiac function of a human 2 -adrenergic receptor polymorphism expressed in transgenic mice. Proc. Natl. Acad. Sci. U.S.A. 93: Liggett, S. B., L. E. Wagoner, L. L. Craft, R. W. Hornung, B. D. Hoit, T. C. McIntosh, and R. A. Walsh The Ile adrenergic receptor polymorphism adversely affects the outcome of congestive heart failure. J. Clin. Invest. 102: Tan, S., I. P. Hall, J. Dewar, E. Dow, and B. Lipworth Association between beta 2-adrenoceptor polymorphism and susceptibility to bronchodilator desensitisation in moderately severe stable asthmatics. Lancet 350: Ohe, M., M. Munakata, N. Hizawa, A. Itoh, I. Doi, E. Yamaguchi, Y. Homma, and Y. Kawakami Beta 2 adrenergic receptor gene restriction fragment length polymorphism and bronchial asthma. Thorax 50: Hancox, R. J., M. R. Sears, and D. R. Taylor Polymorphism of the 2 -adrenoceptor and the response to long-term 2 -agonist therapy in asthma. Eur. Respir. J. 11: Turki, J., J. Pak, S. Green, R. Martin, and S. B. Liggett Genetic polymorphisms of the 2 -adrenergic receptor in nocturnal and nonnocturnal asthma: evidence that Gly 16 correlates with the nocturnal phenotype. J. Clin. Invest. 95: Hall, I. P., A. Wheatley, P. Wilding, and S. B. Liggett Association of the Glu27 2 -adrenoceptor polymorphism with lower airway reactivity in asthmatic subjects. Lancet 345: Dewar, J. C., J. Wilkinson, A. Wheatley, N. S. Thomas, I. Doull, N. Morton, P. Lio, J. Harvey, S. B. Liggett, I. S. Holgate, and I. P. Hall The glutamine 27 2 adrenoceptor polymorphism is associated with elevated immunoglobulin E levels in asthmatic families. J. Allergy Clin. Immunol. 100:
The pharmacogenetics of β 2 -adrenergic receptors: Relevance to asthma
The pharmacogenetics of β 2 -adrenergic receptors: Relevance to asthma Stephen B. Liggett, MD Cincinnati, Ohio The β 2 -adrenergic receptor (β 2 AR) is the molecular target for β-agonists used in the treatment
More informationThe Effect of Polymorphisms of the 2 -Adrenergic Receptor on the Response to Regular Use of Albuterol in Asthma
The Effect of Polymorphisms of the 2 -Adrenergic Receptor on the Response to Regular Use of Albuterol in Asthma ELLIOT ISRAEL, JEFFREY M. DRAZEN, STEPHEN B. LIGGETT, HOMER A. BOUSHEY, REUBEN M. CHERNIACK,
More informationLONG-ACTING BETA AGONISTS
LONG-ACTING BETA AGONISTS AND ICS/LABA COMBINATIONS DISCLOSURE Dr. Francisco has no financial interest in any commercial entity discussed in this presentation Dr. Francisco will not discuss experimental
More informationT he development of tolerance following the use of long
662 ASTHMA Cross tolerance to salbutamol occurs independently of b 2 adrenoceptor genotype-16 in asthmatic patients receiving regular formoterol or salmeterol D K C Lee, C M Jackson, C E Bates, B J Lipworth...
More informationThe New England Journal of Medicine -ADRENERGIC RECEPTOR ON AGONIST-MEDIATED VASCULAR DESENSITIZATION
THE EFFECT OF COMMON POLYMORPHISMS OF THE b 2 ADRENERGIC RECEPTOR ON AGONISTMEDIATED VASCULAR DESENSITIZATION VICTOR DISHY, M.D., GBENGA G. SOFOWORA, M.D., HONGGUANG XIE, M.D., RICHARD B. KIM, M.D., DANIEL
More informationStep up if needed (first, check adherence, environmental control and comorbid conditions) Patients ASSESS CONTROL. Step down if possible
12/9/212 Pharmacogenomics Treating the Individual Asthma Patient Elliot Israel, M.D. Professor of Medicine Harvard Medical School Brigham & Women s Hospital Partners Asthma Center Too much of a good thing?
More informationThe Ile Adrenergic Receptor Polymorphism Adversely Affects the Outcome of Congestive Heart Failure
The Ile164 2 -Adrenergic Receptor Polymorphism Adversely Affects the Outcome of Congestive Heart Failure Stephen B. Liggett, Lynne E. Wagoner,* Laura L. Craft,* Richard W. Hornung, Brian D. Hoit,* Tina
More informationRespiratory Research. Open Access. Abstract. BioMed Central
Respiratory Research BioMed Central Research Limited β 2 -adrenoceptor haplotypes display different agonist mediated airway responses in asthmatics Anneke van Veen 1, Eddy A Wierenga 2, Robert Westland
More informationMolecular mechanisms of b 2 -adrenergic receptor function, response, and regulation
Molecular mechanisms in allergy and clinical immunology (Supported by an unrestricted educational grant from Genentech, Inc. and Novartis Pharmaceuticals Corporation) Series editors: William T. Shearer,
More informationInsulin Resistance. Biol 405 Molecular Medicine
Insulin Resistance Biol 405 Molecular Medicine Insulin resistance: a subnormal biological response to insulin. Defects of either insulin secretion or insulin action can cause diabetes mellitus. Insulin-dependent
More informationMechanisms of Pharmacogenomic Effects of Genetic Variation. of the Cardiac Adrenergic Network in Heart Failure
Molecular Pharmacology This article has not Fast been Forward. copyedited and Published formatted. The on final June version 2, 2009 may differ as doi:10.1124/mol.109.056572 from this version. Mechanisms
More informationA sthma is one of the most common chronic diseases in
940 ASTHMA Arginine-16 b 2 adrenoceptor genotype predisposes to exacerbations in young asthmatics taking regular salmeterol C N A Palmer, B J Lipworth, S Lee, T Ismail, D F Macgregor, S Mukhopadhyay...
More informationPersonalized medicine in childhood asthma. Dr Mariëlle Pijnenburg, Erasmus MC Sophia, Rotterdam, NL
Thank you for viewing this presentation. We would like to remind you that this material is the property of the author. It is provided to you by the ERS for your personal use only, as submitted by the author.
More informationDrug Receptor Interactions and Pharmacodynamics
Drug Receptor Interactions and Pharmacodynamics Dr. Raz Mohammed MSc Pharmacology School of Pharmacy 22.10.2017 Lec 6 Pharmacodynamics definition Pharmacodynamics describes the actions of a drug on the
More informationEffects of β2-adrenergic receptor polymorphisms on asthma severity and response to salbutamol in Egyptian children
Egypt J Pediatr Allergy Immunol 2012;10(2):8186. Original article Effects of β2adrenergic receptor polymorphisms on asthma severity and response to salbutamol in Egyptian children Background: Several polymorphisms
More informationDual-Controller Asthma Therapy: Rationale and Clinical Benefits
B/1 Dual-Controller Asthma Therapy: Rationale and Clinical Benefits MODULE B The 1997 National Heart, Lung, and Blood Institute (NHLBI) Expert Panel guidelines on asthma management recommend a 4-step approach
More informationThe importance of genetic influences in asthma
Eur Respir J 1999; 14: 1210±1227 Printed in UK ± all rights reserved Copyright #ERS Journals Ltd 1999 European Respiratory Journal ISSN 0903-1936 REVIEW The importance of genetic influences in asthma H.
More informationUpdate on current concepts of the molecular basis of β 2 -adrenergic receptor signaling
Beta-adrenergic signaling Update on current concepts of the molecular basis of β 2 -adrenergic receptor signaling Stephen B. Liggett, MD Cincinnati, Ohio The proposed manner by which β 2 -adrenergic receptors
More informationGenetics and Genomics in Medicine Chapter 8 Questions
Genetics and Genomics in Medicine Chapter 8 Questions Linkage Analysis Question Question 8.1 Affected members of the pedigree above have an autosomal dominant disorder, and cytogenetic analyses using conventional
More informationOne interesting observation made by
Eur Respir J 2007; 29: 1239 1245 DOI: 10.1183/09031936.00088206 CopyrightßERS Journals Ltd 2007 SERIES GENETICS OF ASTHMA AND COPD IN THE POSTGENOME ERA Edited by E. von Mutius, M. Kabesch and F. Kauffmann
More informationExhaled Nitric Oxide: An Adjunctive Tool in the Diagnosis and Management of Asthma
Exhaled Nitric Oxide: An Adjunctive Tool in the Diagnosis and Management of Asthma Jason Debley, MD, MPH Assistant Professor, Pediatrics Division of Pulmonary Medicine University of Washington School of
More informationAllergy and Immunology Review Corner: Chapter 75 of Middleton s Allergy Principles and Practice, 7 th Edition, edited by N. Franklin Adkinson, et al.
Allergy and Immunology Review Corner: Chapter 75 of Middleton s Allergy Principles and Practice, 7 th Edition, edited by N. Franklin Adkinson, et al. Chapter 75: Approach to Infants and Children with Asthma
More informationTolerance to bronchodilating effects of salmeterol in COPD
Respiratory Medicine (2003) 97, 1014 1020 Tolerance to bronchodilating effects of salmeterol in COPD J.F. Donohue a, *, S. Menjoge b, S. Kesten b a University of North Carolina School of Medicine, 130
More informationGenetics of COPD Prof. Ian P Hall
Genetics of COPD 1 Prof. Ian P. Hall Dean, Faculty of Medicine and Health Sciences The University of Nottingham Medical School Ian.Hall@nottingham.ac.uk Chronic obstructive pulmonary disease (COPD) 900,000
More informationCurrent Asthma Management: Opportunities for a Nutrition-Based Intervention
Current Asthma Management: Opportunities for a Nutrition-Based Intervention Stanley J. Szefler, MD Approximately 22 million Americans, including 6 million children, have asthma. It is one of the most prevalent
More informationThe major histocompatibility complex (MHC) is a group of genes that governs tumor and tissue transplantation between individuals of a species.
Immunology Dr. John J. Haddad Chapter 7 Major Histocompatibility Complex The major histocompatibility complex (MHC) is a group of genes that governs tumor and tissue transplantation between individuals
More informationSalmeterol, a new long acting inhaled,f2 adrenoceptor agonist: comparison with salbutamol in adult asthmatic patients
Thorax 1988;43:674-678 Salmeterol, a new long acting inhaled,f2 adrenoceptor agonist: comparison with salbutamol in adult asthmatic patients ANDERS ULLMAN, NILS SVEDMYR From the Department of Clinical
More informationAt least 3 of the following criteria:
Management of Severe Asthma Heung-Woo Park Department of Internal Medicine, Seoul National University Hospital, Seoul, Republic of Korea How to define severe asthma At least 3 of the following criteria:
More informationCONCLUSIONS: For the primary end point in the total population, there were no significant differences between treatments. There were small, but statis
V. Clinical Sciences A. Allergic Diseases and Related Disorders 1. Upper airway disease a. Clinical skills and interpretive strategies for diagnosis of upper airway diseases: skin testing (epicutaneous
More informationBIOL212 Biochemistry of Disease. Metabolic Disorders - Obesity
BIOL212 Biochemistry of Disease Metabolic Disorders - Obesity Obesity Approx. 23% of adults are obese in the U.K. The number of obese children has tripled in 20 years. 10% of six year olds are obese, rising
More informationPharmacogenetics of 2-Agonists
Allergology International. 2011;60:239-246 DOI: 10.2332 allergolint.11-rai-0317 REVIEW ARTICLE Pharmacogenetics of 2-Agonists Nobuyuki Hizawa 1 ABSTRACT Short-acting β2-agonists (SABAs) and long-acting
More informationTolerance to beta-agonists during acute bronchoconstriction
Eur Respir J 1999; 14: 283±287 Printed in UK ± all rights reserved Copyright #ERS Journals Ltd 1999 European Respiratory Journal ISSN 0903-1936 Tolerance to beta-agonists during acute bronchoconstriction
More informationThe Biology and Genetics of Cells and Organisms The Biology of Cancer
The Biology and Genetics of Cells and Organisms The Biology of Cancer Mendel and Genetics How many distinct genes are present in the genomes of mammals? - 21,000 for human. - Genetic information is carried
More informationChapter 2 Gene and Promoter Structures of the Dopamine Receptors
Chapter 2 Gene and Promoter Structures of the Dopamine Receptors Ursula M. D Souza Abstract The dopamine receptors have been classified into two groups, the D 1 - like and D 2 -like dopamine receptors,
More informationIntroduction to Genetics
Introduction to Genetics Table of contents Chromosome DNA Protein synthesis Mutation Genetic disorder Relationship between genes and cancer Genetic testing Technical concern 2 All living organisms consist
More informationG Protein-Coupled Receptors as Drug Targets
G Protein-Coupled Receptors as Drug Targets Analysis of Activation and Constitutive Activity Edited by Roland Seifert and Thomas Wieland WILEY- VCH WILEY-VCH Verlag GmbH & Co. KGaA Table of Contents Preface
More informationLack of Subsensitivity to Albuterol After Treatment with Salmeterol in Patients with Asthma
Lack of Subsensitivity to Albuterol After Treatment with Salmeterol in Patients with Asthma HAROLD S. NELSON, ROBERT B. BERKOWITZ, DAVID A. TINKELMAN, AMANDA H. EMMETT, KATHLEEN A. RICKARD, and STEVEN
More informationSALSA MLPA KIT P050-B2 CAH
SALSA MLPA KIT P050-B2 CAH Lot 0510, 0909, 0408: Compared to lot 0107, extra control fragments have been added at 88, 96, 100 and 105 nt. The 274 nt probe gives a higher signal in lot 0510 compared to
More informationSodium Fluoride Improves Methacholine Induced Bronchoconstriction Similar To Salbutamol In Patients With Asthma
ISPUB.COM The Internet Journal of Asthma, Allergy and Immunology Volume 5 Number 1 Sodium Fluoride Improves Methacholine Induced Bronchoconstriction Similar To Salbutamol In Patients R Sonia, T Zouhair,
More informationHLA and antigen presentation. Department of Immunology Charles University, 2nd Medical School University Hospital Motol
HLA and antigen presentation Department of Immunology Charles University, 2nd Medical School University Hospital Motol MHC in adaptive immunity Characteristics Specificity Innate For structures shared
More informationThe Acute & Maintenance Treatment of Asthma via Aerosolized Medications
The Acute & Maintenance Treatment of Asthma via Aerosolized Medications Douglas S. Gardenhire, EdD, RRT-NPS, FAARC Associate Professor and Chairman Department of Respiratory Therapy Objectives Define Asthma.
More informationThis exam consists of two parts. Part I is multiple choice. Each of these 25 questions is worth 2 points.
MBB 407/511 Molecular Biology and Biochemistry First Examination - October 1, 2002 Name Social Security Number This exam consists of two parts. Part I is multiple choice. Each of these 25 questions is
More information5/2/18. After this class students should be able to: Stephanie Moon, Ph.D. - GWAS. How do we distinguish Mendelian from non-mendelian traits?
corebio II - genetics: WED 25 April 2018. 2018 Stephanie Moon, Ph.D. - GWAS After this class students should be able to: 1. Compare and contrast methods used to discover the genetic basis of traits or
More informationSUPPLEMENTARY INFORMATION
SUPPLEMENTARY INFORMATION doi:10.1038/nature22394 Supplementary Table 1 Observed intermolecular interactions within the GLP-1:GLP-1R TMD interface. Superscripts refer to the Wootten residue numbering system
More informationHandling Immunogenetic Data Managing and Validating HLA Data
Handling Immunogenetic Data Managing and Validating HLA Data Steven J. Mack PhD Children s Hospital Oakland Research Institute 16 th IHIW & Joint Conference Sunday 3 June, 2012 Overview 1. Master Analytical
More informationHLA and antigen presentation. Department of Immunology Charles University, 2nd Medical School University Hospital Motol
HLA and antigen presentation Department of Immunology Charles University, 2nd Medical School University Hospital Motol MHC in adaptive immunity Characteristics Specificity Innate For structures shared
More informationUniversity of Dundee. Published in: Lung. DOI: /s Publication date: 2016
University of Dundee Is Gly16Arg 2 Receptor Polymorphism Related to Impulse Oscillometry in a Real-Life Asthma Clinic Setting? Jabbal, Sunny; Manoharan, Arvind; Lipworth, Joseph; Anderson, William; Short,
More informationThe functional investigation of the interaction between TATA-associated factor 3 (TAF3) and p53 protein
THESIS BOOK The functional investigation of the interaction between TATA-associated factor 3 (TAF3) and p53 protein Orsolya Buzás-Bereczki Supervisors: Dr. Éva Bálint Dr. Imre Miklós Boros University of
More informationDan Koller, Ph.D. Medical and Molecular Genetics
Design of Genetic Studies Dan Koller, Ph.D. Research Assistant Professor Medical and Molecular Genetics Genetics and Medicine Over the past decade, advances from genetics have permeated medicine Identification
More information"Role for β2ar biased signaling to address the β-agonist controversy in asthma"
"Role for β2ar biased signaling to address the β-agonist controversy in asthma" Julia K. L. Walker, Ph.D. Professor in Duke University School of Nursing and Pulmonary Medicine Support provided by NHLBI
More informationGenetic variants on 17q21 are associated with asthma in a Han Chinese population
Genetic variants on 17q21 are associated with asthma in a Han Chinese population F.-X. Li 1 *, J.-Y. Tan 2 *, X.-X. Yang 1, Y.-S. Wu 1, D. Wu 3 and M. Li 1 1 School of Biotechnology, Southern Medical University,
More informationBETA 2 -AGONISTS IN ASTHMA TREATMENT
BETA 2 -AGONISTS IN ASTHMA TREATMENT Edited by Romain Pauwels University Hospital Ghent, Belgium Paul M. O'Byrne McMaster University Hamilton, Ontario, Canada :MARCEL DEKKER, INC. NEW YORK BASEL HONG KONG
More informationEmily DiMango, MD Asthma II
Emily DiMango, MD Asthma II Director John Edsall/John Wood Asthma Center Columbia University Medical Center HP 2000 Goal: 2.25/1,000 Comparison of Asthma Hospitalization Rates in Children Aged 0-14 in
More informationObjective: You will be able to explain how the subcomponents of
Objective: You will be able to explain how the subcomponents of nucleic acids determine the properties of that polymer. Do Now: Read the first two paragraphs from enduring understanding 4.A Essential knowledge:
More informationSignificance of the MHC
CHAPTER 7 Major Histocompatibility Complex (MHC) What is is MHC? HLA H-2 Minor histocompatibility antigens Peter Gorer & George Sneell (1940) Significance of the MHC role in immune response role in organ
More informationPharmacogenetics of asthma therapeutics
Pharmacogenetics of asthma therapeutics Anthony G Fenech BPharm(Hons), MPhil, PhD(Nott) Roger Ellul-Micallef MD(Malta), PhD(Edin), FRCP(Edin), FRCP(Lond) Department of Clinical Pharmacology and Therapeutics
More informationDefining Asthma: Clinical Criteria. Defining Asthma: Bronchial Hyperresponsiveness
Defining Asthma: Clinical Criteria Atopy 34% Recent wheeze 20% Asthma 11% AHR 19% n = 807 From: Woolcock, AJ. Asthma in Textbook of Respiratory Medicine, 2nd ed. Murray, Nadel, eds.(saunders:philadelphia)
More informationLife-long asthma and its relationship to COPD. Stephen T Holgate School of Medicine University of Southampton
Life-long asthma and its relationship to COPD Stephen T Holgate School of Medicine University of Southampton Definitions COPD is a preventable and treatable disease with some significant extrapulmonary
More informationBioluminescence Resonance Energy Transfer (BRET)-based studies of receptor dynamics in living cells with Berthold s Mithras
Bioluminescence Resonance Energy Transfer (BRET)-based studies of receptor dynamics in living cells with Berthold s Mithras Tarik Issad, Ralf Jockers and Stefano Marullo 1 Because they play a pivotal role
More informationOmalizumab (Xolair ) ( Genentech, Inc., Novartis Pharmaceuticals Corp.) September Indication
( Genentech, Inc., Novartis Pharmaceuticals Corp.) September 2003 Indication The FDA recently approved Omalizumab on June 20, 2003 for adults and adolescents (12 years of age and above) with moderate to
More informationTumor suppressor genes D R. S H O S S E I N I - A S L
Tumor suppressor genes 1 D R. S H O S S E I N I - A S L What is a Tumor Suppressor Gene? 2 A tumor suppressor gene is a type of cancer gene that is created by loss-of function mutations. In contrast to
More informationBIOMEDICAL SCIENCES GRADUATE PROGRAM SUMMER 2014
THE OHIO STATE UNIVERSITY BIOMEDICAL SCIENCES GRADUATE PROGRAM SUMMER 2014 Elizabeth Stofko Barrie PhD Candidate Genetic Factors Regulating Expression of Dopaminergic Genes July 15 th, 2014 159 DHLRI 1:00
More informationAsthma. Rachel Miller, MD, FAAAAI Director Allergy and Immunology New York Presbyterian Hospital. Figure 1 Asthma Prevalence,
Asthma Rachel Miller, MD, FAAAAI Director Allergy and Immunology New York Presbyterian Hospital Figure 1 Asthma Prevalence, 1980-2000 * Gap between 1995-1996 and 1997 indicates a break in trend due to
More informationSearching for Targets to Control Asthma
Searching for Targets to Control Asthma Timothy Craig Distinguished Educator Professor Medicine and Pediatrics Penn State University Hershey, PA, USA Inflammation and Remodeling in Asthma The most important
More informationAbhd2 regulates alveolar type Ⅱ apoptosis and airway smooth muscle remodeling: a key target of COPD research
Abhd2 regulates alveolar type Ⅱ apoptosis and airway smooth muscle remodeling: a key target of COPD research Shoude Jin Harbin Medical University, China Background COPD ------ a silent killer Insidious,
More informationAntigen Presentation to T lymphocytes
Antigen Presentation to T lymphocytes Immunology 441 Lectures 6 & 7 Chapter 6 October 10 & 12, 2016 Jessica Hamerman jhamerman@benaroyaresearch.org Office hours by arrangement Antigen processing: How are
More informationLeukotriene C 4 synthase polymorphisms and responsiveness to leukotriene antagonists in asthma
Blackwell Science, LtdOxford, UKBCPBritish Journal of Clinical Pharmacology0306-5251Blackwell Publishing 2003? 2003564422426Original ArticleLeukotriene C4 synthasej. J. Lima et al. Leukotriene C 4 synthase
More informationMRC-Holland MLPA. Description version 08; 30 March 2015
SALSA MLPA probemix P351-C1 / P352-D1 PKD1-PKD2 P351-C1 lot C1-0914: as compared to the previous version B2 lot B2-0511 one target probe has been removed and three reference probes have been replaced.
More informationMUTATIONS, MUTAGENESIS, AND CARCINOGENESIS. (Start your clickers)
MUTATIONS, MUTAGENESIS, AND CARCINOGENESIS (Start your clickers) How do mutations arise? And how do they affect a cell and its organism? Mutations: heritable changes in genes Mutations occur in DNA But
More information7.013 Spring 2005 Problem Set 6
MIT Department of Biology 7.013: Introductory Biology - Spring 2005 Instructors: Professor Hazel Sive, Professor Tyler Jacks, Dr. Claudette Gardel NAME TA 7.013 Spring 2005 Problem Set 6 FRIDAY April 29th,
More informationDOES THE BRCAX GENE EXIST? FUTURE OUTLOOK
CHAPTER 6 DOES THE BRCAX GENE EXIST? FUTURE OUTLOOK Genetic research aimed at the identification of new breast cancer susceptibility genes is at an interesting crossroad. On the one hand, the existence
More informationBiological systems interact, and these systems and their interactions possess complex properties. STOP at enduring understanding 4A
Biological systems interact, and these systems and their interactions possess complex properties. STOP at enduring understanding 4A Homework Watch the Bozeman video called, Biological Molecules Objective:
More informationOutline FEF Reduced FEF25-75 in asthma. What does it mean and what are the clinical implications?
Reduced FEF25-75 in asthma. What does it mean and what are the clinical implications? Fernando Holguin MD MPH Director, Asthma Clinical & Research Program Center for lungs and Breathing University of Colorado
More informationCS2220 Introduction to Computational Biology
CS2220 Introduction to Computational Biology WEEK 8: GENOME-WIDE ASSOCIATION STUDIES (GWAS) 1 Dr. Mengling FENG Institute for Infocomm Research Massachusetts Institute of Technology mfeng@mit.edu PLANS
More informationChapter 7 Conclusions
VII-1 Chapter 7 Conclusions VII-2 The development of cell-based therapies ranging from well-established practices such as bone marrow transplant to next-generation strategies such as adoptive T-cell therapy
More informationPhenylketonuria (PKU) the Biochemical Basis. Biol 405 Molecular Medicine
Phenylketonuria (PKU) the Biochemical Basis Biol 405 Molecular Medicine PKU a history In 1934 Følling identified a clinical condition - imbecillitas phenylpyruvica. Mental retardation associated with this
More informationN.G. Gorovenko, G.Y. Stupnytska, S.V. Podolskaya
2014; 3(8): 10-14 ISSN: 2277-7695 TPI 2014; 3(8): 10-14 2013 TPI www.thepharmajournal.com Received: 19-08-2014 Accepted: 26-09-2014 N.G. Gorovenko (a)department of Genetic Diagnosis, State Institute of
More informationTITLE: A Mouse Model to Investigate the Role of DBC2 in Breast Cancer
AD Award Number: W81XWH-04-1-0325 TITLE: A Mouse Model to Investigate the Role of DBC2 in Breast Cancer PRINCIPAL INVESTIGATOR: Valerie Boka CONTRACTING ORGANIZATION: University of Texas Health Science
More informationSUPPLEMENTARY INFORMATION
doi:10.1038/nature10643 Supplementary Table 1. Identification of hecw-1 coding polymorphisms at amino acid positions 322 and 325 in 162 strains of C. elegans. WWW.NATURE.COM/NATURE 1 Supplementary Figure
More informationDefining Asthma: Clinical Criteria. Defining Asthma: Bronchial Hyperresponsiveness
Defining Asthma: Clinical Criteria Atopy 34% Recent wheeze 20% Asthma 11% AHR 19% n = 807 From: Woolcock, AJ. Asthma in Textbook of Respiratory Medicine, 2nd ed. Murray, Nadel, eds.(saunders:philadelphia)
More informationDefining Asthma: Bronchial Hyperresponsiveness. Defining Asthma: Clinical Criteria. Impaired Ventilation in Asthma. Dynamic Imaging of Asthma
Defining Asthma: Clinical Criteria Defining Asthma: Bronchial Hyperresponsiveness Atopy 34% Recent wheeze 20% Asthma 11% AHR 19% n = 807 From: Woolcock, AJ. Asthma in Textbook of Respiratory Medicine,
More informationGenome-wide Association Analysis Applied to Asthma-Susceptibility Gene. McCaw, Z., Wu, W., Hsiao, S., McKhann, A., Tracy, S.
Genome-wide Association Analysis Applied to Asthma-Susceptibility Gene McCaw, Z., Wu, W., Hsiao, S., McKhann, A., Tracy, S. December 17, 2014 1 Introduction Asthma is a chronic respiratory disease affecting
More informationIVF Michigan, Rochester Hills, Michigan, and Reproductive Genetics Institute, Chicago, Illinois
FERTILITY AND STERILITY VOL. 80, NO. 4, OCTOBER 2003 Copyright 2003 American Society for Reproductive Medicine Published by Elsevier Inc. Printed on acid-free paper in U.S.A. CASE REPORTS Preimplantation
More informationAsthma affects around 6-31% of Indian children
R E S E A R C H P A P E R ADRB2 Polymorphism and Salbutamol Responsiveness in Northern Indian Children with Mild to Moderate Exacerbation of Asthma PUNEET KAUR SAHI, SHIVARAM SHASTRI, RAKESH LODHA, NEERJA
More informationSoluble ADAM33 initiates airway remodeling to promote susceptibility for. Elizabeth R. Davies, Joanne F.C. Kelly, Peter H. Howarth, David I Wilson,
Revised Suppl. Data: Soluble ADAM33 1 Soluble ADAM33 initiates airway remodeling to promote susceptibility for allergic asthma in early life Elizabeth R. Davies, Joanne F.C. Kelly, Peter H. Howarth, David
More informationAsthma Phenotypes, Heterogeneity and Severity: The Basis of Asthma Management
Asthma Phenotypes, Heterogeneity and Severity: The Basis of Asthma Management Eugene R. Bleecker, MD Professor and Director, Center for Genomics & Personalized Medicine Research Professor, Translational
More informationORIGINAL ARTICLE INTRODUCTION
Allergology International. 2013;62:113-121 DOI: 10.2332allergolint.12-OA-0467 ORIGINAL ARTICLE Asthma Phenotypes in Japanese Adults - Their Associations with the CCL5 and ADRB2 Genotypes Yoshiko Kaneko
More informationTHE NHLBI GUIDELINES: WHERE DO WE STAND AND WHAT IS THE NEW DIRECTION FROM THE NAEPP?
THE NHLBI GUIDELINES: WHERE DO WE STAND AND WHAT IS THE NEW DIRECTION FROM THE NAEPP? Peter S. Creticos, MD ABSTRACT In 1991 and 1997, the National Heart, Lung, and Blood Institute s National Asthma Education
More informationSupplementary Medications during asthma attack. Prof. Dr Finn Rasmussen PhD. DrMedSc. Near East University Hospital North Cyprus
Supplementary Medications during asthma attack Prof. Dr Finn Rasmussen PhD. DrMedSc. Near East University Hospital North Cyprus Conflicts of Interest None Definition of Asthma Airway narrowing that is
More informationMRC-Holland MLPA. Description version 07; 26 November 2015
SALSA MLPA probemix P266-B1 CLCNKB Lot B1-0415, B1-0911. As compared to version A1 (lot A1-0908), one target probe for CLCNKB (exon 11) has been replaced. In addition, one reference probe has been replaced
More informationAsthma Update A/Prof. John Abisheganaden. Senior Consultant, Dept Of Respiratory & Crit Care Medicine Tan Tock Seng Hospital
Asthma Update - 2013 A/Prof. John Abisheganaden Senior Consultant, Dept Of Respiratory & Crit Care Medicine Tan Tock Seng Hospital Asthma A complex syndrome Multifaceted disease Heterogeneous Genetic and
More informationGeorge R. Honig Junius G. Adams III. Human Hemoglobin. Genetics. Springer-Verlag Wien New York
George R. Honig Junius G. Adams III Human Hemoglobin Genetics Springer-Verlag Wien New York George R. Honig, M.D., Ph.D. Professor and Head Department of Pediatrics, College of Medicine University of Illinois
More informationHands-On Ten The BRCA1 Gene and Protein
Hands-On Ten The BRCA1 Gene and Protein Objective: To review transcription, translation, reading frames, mutations, and reading files from GenBank, and to review some of the bioinformatics tools, such
More informationCover Page. The handle holds various files of this Leiden University dissertation.
Cover Page The handle http://hdl.handle.net/1887/35456 holds various files of this Leiden University dissertation. Author: Hassan, Suha Mustafa Title: Toward prevention of Hemoglobinopathies in Oman Issue
More informationKirthi Gunasekera MD Respiratory Physician National Hospital of Sri Lanka Colombo,
Kirthi Gunasekera MD Respiratory Physician National Hospital of Sri Lanka Colombo, BRONCHODILATORS: Beta Adrenoreceptor Agonists Actions Adrenoreceptor agonists have many of the same actions as epinephrine/adrenaline,
More informationThe Basics: A general review of molecular biology:
The Basics: A general review of molecular biology: DNA Transcription RNA Translation Proteins DNA (deoxy-ribonucleic acid) is the genetic material It is an informational super polymer -think of it as the
More informationBiology 2C03: Genetics What is a Gene?
Biology 2C03: Genetics What is a Gene? September 9 th, 2013 Model Organisms - E. coli - Yeast - Worms - Arabodopsis - Fruitflie - Mouse What is a Gene? - Define, recognize, describe and apply Mendel s
More informationJay M. Baraban MD, PhD January 2007 GENES AND BEHAVIOR
Jay M. Baraban MD, PhD jay.baraban@gmail.com January 2007 GENES AND BEHAVIOR Overview One of the most fascinating topics in neuroscience is the role that inheritance plays in determining one s behavior.
More informationBiochemistry 2000 Sample Question Transcription, Translation and Lipids. (1) Give brief definitions or unique descriptions of the following terms:
(1) Give brief definitions or unique descriptions of the following terms: (a) exon (b) holoenzyme (c) anticodon (d) trans fatty acid (e) poly A tail (f) open complex (g) Fluid Mosaic Model (h) embedded
More informationTitle:The effect of CD14 and TLR4 gene polimorphisms on asthma phenotypes in adult Turkish asthma patients: a genetic study
Author's response to reviews Title:The effect of CD14 and TLR4 gene polimorphisms on asthma phenotypes in adult Turkish asthma patients: a genetic study Authors: Fusun Sahin (fusunsahin19700@hotmail.com)
More information